Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 9, 2022 | Post-IPO Equity | $100M | 1 | Kite Pharma | — | Detail |
Jun 15, 2022 | Post-IPO Equity | $112M | — | — | — | Detail |
Mar 10, 2022 | Post-IPO Equity | $9.99M | — | — | — | Detail |
Feb 4, 2022 | IPO | $124M | — | — | — | Detail |
Apr 13, 2021 | Series C | — | 7 | CAM Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Kite Pharma | Yes | Post-IPO Equity |
CAM Capital | Yes | Series C |
Aju IB Investment | Yes | Series B |
Quan Capital | Yes | Series B |
Adage Capital Management | — | Series C |
Asymmetry Ventures | — | Series C |
CaaS Capital Management | — | Series C |
Cambrian Biopharma | — | Series C |
Clough Capital Partners | — | Series C |
LG Technology Ventures | — | Series C |